Development of an UPLC–MS/MS assay to determine psoralidin in rat plasma and its application in a pharmacokinetic study after intragastric administration

• Autorzy: Feng Feng , Jiang Xiunan , Qiu Jieying , Wu Hongyu , Cai Xiaojun , Xiang Zheng

Identyfikatory

DOI

10.1556/1326.2019.00679

• Języki publikacji: EN

Abstrakty

EN

Psoralidin has a variety of pharmacological activities, such as anti-tumor, anti-depressant, and anti-inflammatory activities. This study aims at developing a rapid ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method to determine psoralidin in rat plasma and studying the pharmacokinetic characteristic of psoralidin after intragastric administration of 20 and 40 mg/kg. Alpinetin was used as an internal standard (IS), and the plasma samples were precipitated with acetonitrile. The calibration curves were linear over the range of 0.2–250 ng/mL (R2 = 0.993). The pharmacokinetic parameters were calculated by DAS 3.0. Half-life (t1/2) was 7.2 ± 0.97 h and 7.1 ± 0.27 h for different dosages, respectively. Tmax was 4.2 ± 1.1 h and 4.0 ± 1.1 h for different dosages, respectively. Apparent volume of distribution (Vd) for different dosages was 630.1 ± 168.8 and 600.1 ± 138.8 L/kg, respectively. Clearance (CL) was 105.6 ± 29.2 and 100.6 ± 22.2 L/h/kg for different dosages, indicating that psoralidin was mainly distributed in rat tissues. The pharmacokinetic study provided important information for further clinical application in the treatment of cancer and osteoporosis.

Słowa kluczowe

EN

psoralidin; UPLC–MS/MS; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2020
• Tom: Vol. 32, no. 4
• Strony: 215--218
• Opis fizyczny: Bibliogr. 27 poz., rys.

Twórcy

autor

Feng Feng

• Wenzhou Medical University, Wenzhou 325035, China

autor

Jiang Xiunan

• Wenzhou Medical University, Wenzhou 325035, China

autor

Qiu Jieying

• Wenzhou Medical University, Wenzhou 325035, China

autor

Wu Hongyu

• Wenzhou Medical University, Wenzhou 325035, China

autor

Cai Xiaojun

• Wenzhou Medical University, Wenzhou 325035, China

autor

Xiang Zheng

• Wenzhou Medical University, Wenzhou 325035, China

Bibliografia

• [1] Lin, Q.; Li, J.; Li, H. J. Xianning University 2012, 26, 175–177.
• [2] Pahari, P.; Saikia, U. P.; Das, T. P.; Damodaran, C.; Rohr, J. Tetrahedron 2016, 72, 3324–3334.
• [3] Hao, W. H.; Zhang, X. N.; Zhao, W. W.; Chen, X. P. PeerJ 2014, 2.
• [4] Wang, X.; Xu, C.; Hua, Y.; Sun, L.; Cheng, K.; Jia, Z.; Han, Y.; Dong, J.; Cui, Y.; Yang, Z. J. Exp. Clin. Cancer Res. 2016, 35, 186.
• [5] Jin, Z. L.; Yan, W.; Jin, H.; Ge, C. Z.; Xu, Y. H. Oncol. Lett. 2016, 12, 971–976.
• [6] Sowmyalakshmi, S.; Kumar, R.; Pahari, P.; Rohr, J.; Damodaran, C. Cancer Res. 2010, 70.
• [7] Damodaran, C.; Kumar, R.; Rohr, J. Cancer Res. 2010, 70.
• [8] Wang, D.; Li, F.; Jiang, Z. Planta Med. 2001, 67, 748–9.
• [9] Zhai, Y. K.; Li, Y. Y.; Wang, Y. P.; Cui, J. W.; Feng, K.; Kong, X. J.; Chen, L. Eur. J. Pharmacol. 2017, 801, 62–71.
• [10] Zhai, Y. K.; Wang, Q. F.; Li, Y. Y.; Cui, J.; Feng, K.; Kong, X. J.; Xian, C. J. Biomed. Pharmacother. 2018, 102, 1015–1024.
• [11] Rao, Z. T.; Wang, S. Q.; Wang, J. Q. Mol. Med. Rep. 2018, 17, 3418–3424.
• [12] Kong, L. B.; Ma, R.; Yang, X. B.; Zhu, Z. Q.; Guo, H.; He, B. R.; Wang, B.; Hao, D. J. Int. Immunopharmacol. 2017, 51, 31–39.
• [13] Ren, G. W.; Luo, W. W.; Sun, W.; Niu, Y. A.; Ma, D. L.; Leung, C. H.; Wang, Y. T.; Lu, J. J.; Chen, X. P. Phytomedicine 2016, 23, 939–947.
• [14] Chen, X.; Zhang, X.; Hao, W.; Lu, J. Basic Clin. Pharmacol. 2014, 115, 314–314.
• [15] Zhang, R.; Shi, W.; Li, L.; Huang, X.; Xu, D.; Wu, L. Pharmazie 2019, 74, 67–72.
• [16] Fasheng, L.; Guang, Y.; Xu, H. Zhongguo Yaoshi 2008, 11, 140–142.
• [17] Szliszka, E.; Czuba, Z. P.; Sędek, Ł.; Paradysz, A.; Król, W. Pharmacol Rep 2011, 63, 139–148.
• [18] Hao, W.; Zhang, X.; Zhao, W.; Chen, X. PeerJ 2014, 2, e555.
• [19] Jin, Z.; Yan, W.; Jin, H.; Ge, C.; Xu, Y. Oncol. Lett. 2016, 12, 971–976.
• [20] Wang, T.; Yin, Z.; Zhang, W. Zhongguo Zhongyao Zazhi 2013, 38, 2328–2333.
• [21] Li, J.; Wang, X.; Zeng, Y. Zhongguo Zhongyao Zazhi 2013, 38, 1816–1819.
• [22] Yang, Y. F.; Zhang, Y. B.; Chen, Z. J.; Zhang, Y. T.; Yang, X. W. Phytomedicine 2018, 38, 166–174.
• [23] Shi, X. B.; Zhang, G.; Mackie, B.; Yang, S. M.; Wang, J.; Shan, L. N. J. Chromatogr. B 2016, 1029, 145–156.
• [24] Administration F. a. D. Bioanalytical Method Validation Guidance for Industry, USA, 2018.
• [25] Shi X. Study on the metabolism of morin and Psoralen in vitro, China Medical University, Shenyang, 2015.
• [26] Li M. Inhibition of Fructus psoralen on uridine two phosphate glucuronosyltransferase (UGT), Liaoning Medical University, Jinzhou, 2015.
• [27] Dietrich, S.; Floegel, A.; Troll, M.; Kuhn, T.; Rathmann, W.; Peters, A.; Sookthai, D.; Bergen, M.; Kaaks, R.; Adamski, J.; Prehn, C.; Boeing, H.; Schulze, M. B.; Illig, T.; Pischon, T.; Knuppel, S.; Wang-Sattler, R.; Drogan, D. Int. J. Epidemiol. 2016, 45, 1406–1420.

Uwagi

PL

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).